Exchange: NASDAQ·Updated 06:27 PM EDT
NUVL logo

NUVL Nuvalent Inc - Ordinary Shares - Class A

$123.96
$0.02
(0.02%)
Today
Closed $123.96
$0.01
(0.01%)
After Hours
Reported EarningsMay 7
Mkt Cap$9.79B
Vol3.09M

About NUVL

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
46

Neutral Sentiment

How do you feel about NUVL?

Advertisement|Remove ads.